China Medicine Receives rADTZ Feasibility Report from the Feed Research Institute, Chinese Academy of Agricultura...( GUANGZHOU China July 16 Asia/ -- ...),Health

GUANGZHOU, China, July 16 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary-supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), announced today that it has received a third party feasibility report on recombinant Aflatoxin Detoxifizyme (rADTZ) from the Feed Research Institute (FRI) of the Chinese Academy of Agricultural Sciences (CAAS).

rADTZ is an innovative new product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed when used as an additive. The report showed that experiments on baby chickens and piglets were positive where usage of the rADTZ enzyme in animal feed showed efficacy. Specifically, baby chickens and piglets experienced healthy growth in body and organ weight with rADTZ treated feed. In addition, the immunity system of animals in both working groups increased substantially, helping to decrease mortality rates. Based on the documented benefits of rADTZ, a separate study found that a breeder farm with the capacity of breeding 50 million chickens is expected to save up to 35 million RMB ($5.1 million) in costs through using rADTZ.

"With this feasibility report, we have begun trial production of rADTZ and trial sales will follow very soon in China," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "We are also eligible to apply for a product permit for rADTZ from the Ministry of Agriculture in China and expect to receive it in approximately six months. With the product permit, rADTZ can be sold nationally in China. We expect rADTZ to achieve net margins of 70% in 2009. We are remain very enthusiastic about the prospects of our novel product and believe rADTZ will
'/>"/>